Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

705 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.
Meindl M, Bläske A, Steiger K, Lindner S, Lindheimer F, Lauber K, Brix N, von Ungern-Sternberg B, Oos R, Palumbo G, Böning G, Schüle S, Majewski M, Port M, Ziegler S, Bartenstein P. Meindl M, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):395-404. doi: 10.1007/s00259-023-06430-x. Epub 2023 Oct 5. Eur J Nucl Med Mol Imaging. 2024. PMID: 37796306 Free PMC article.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Zellmer J, et al. Among authors: bartenstein p. Biomedicines. 2022 Dec 1;10(12):3102. doi: 10.3390/biomedicines10123102. Biomedicines. 2022. PMID: 36551858 Free PMC article.
Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy.
Brosch-Lenz J, Delker A, Völter F, Unterrainer LM, Kaiser L, Bartenstein P, Ziegler S, Rahmim A, Uribe C, Böning G. Brosch-Lenz J, et al. Among authors: bartenstein p. J Nucl Med. 2023 May;64(5):767-774. doi: 10.2967/jnumed.122.264594. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657980 Free PMC article.
Machine learning-based approach reveals essential features for simplified TSPO PET quantification in ischemic stroke patients.
Zatcepin A, Kopczak A, Holzgreve A, Hein S, Schindler A, Duering M, Kaiser L, Lindner S, Schidlowski M, Bartenstein P, Albert N, Brendel M, Ziegler SI. Zatcepin A, et al. Among authors: bartenstein p. Z Med Phys. 2024 May;34(2):218-230. doi: 10.1016/j.zemedi.2022.11.008. Epub 2023 Jan 20. Z Med Phys. 2024. PMID: 36682921 Free article.
Feasibility of radiomic feature harmonization for pooling of [18F]FET or [18F]GE-180 PET images of gliomas.
Zounek AJ, Albert NL, Holzgreve A, Unterrainer M, Brosch-Lenz J, Lindner S, Bollenbacher A, Boening G, Rupprecht R, Brendel M, von Baumgarten L, Tonn JC, Bartenstein P, Ziegler S, Kaiser L. Zounek AJ, et al. Among authors: bartenstein p. Z Med Phys. 2023 Feb;33(1):91-102. doi: 10.1016/j.zemedi.2022.12.005. Epub 2023 Jan 27. Z Med Phys. 2023. PMID: 36710156 Free PMC article.
Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.
Resch S, Takayama Fouladgar S, Zacherl M, Sheikh GT, Liubchenko G, Rumiantcev M, Unterrainer LM, Wenter V, Bartenstein P, Ziegler SI, Ilhan H, Beyer L, Böning G, Delker A. Resch S, et al. Among authors: bartenstein p. EJNMMI Phys. 2023 Feb 9;10(1):11. doi: 10.1186/s40658-023-00529-8. EJNMMI Phys. 2023. PMID: 36757516 Free PMC article.
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. Solomonidou N, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2529-2536. doi: 10.1007/s00259-023-06185-5. Epub 2023 Mar 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36905411 Free PMC article.
Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.
Spohn SKB, Schmidt-Hegemann NS, Ruf J, Mix M, Benndorf M, Bamberg F, Makowski MR, Kirste S, Rühle A, Nouvel J, Sprave T, Vogel MME, Galitsnaya P, Gschwend JE, Gratzke C, Stief C, Löck S, Zwanenburg A, Trapp C, Bernhardt D, Nekolla SG, Li M, Belka C, Combs SE, Eiber M, Unterrainer L, Unterrainer M, Bartenstein P, Grosu AL, Zamboglou C, Peeken JC. Spohn SKB, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2537-2547. doi: 10.1007/s00259-023-06195-3. Epub 2023 Mar 16. Eur J Nucl Med Mol Imaging. 2023. PMID: 36929180 Free PMC article.
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
Holzgreve A, Taugner J, Käsmann L, Müller P, Tufman A, Reinmuth N, Li M, Winkelmann M, Unterrainer LM, Nieto AE, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Unterrainer M, Manapov F. Holzgreve A, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2466-2476. doi: 10.1007/s00259-023-06192-6. Epub 2023 Mar 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36951991 Free PMC article.
705 results